Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Loaiza-Bonilla on Right- Versus Left-Sided Colorectal Cancer

January 24th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specialized in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses findings of patients with right- versus left-sided tumors of colorectal cancer (CRC).

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Dr. Terashima on Bursectomy for Subserosal and Serosal Gastric Cancer

January 24th 2017

Masanori Terashima, MD, PhD, FACS, chairman of the Japanese Clinical Oncology Group, discusses bursectomy for patients with subserosal and serosal gastric cancer.

Trend Toward Better PFS With Four-Drug CRC Regimen

January 24th 2017

Patients with advanced colorectal cancer had a modest gain in progression-free survival with the addition of irinotecan to standard chemotherapy plus an angiogenesis inhibitor as induction therapy, a randomized trial showed.

Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

January 24th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations of treatments for patients with gastric and esophageal cancers.

Dr. Muro on Results of PaFF-K Study in Colorectal Cancer

January 23rd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the results of the PaFF-K study in metastatic colorectal cancer.

Dr. Loaiza-Bonilla on Differences in Mutation Rates Between Right- and Left-Sided CRC

January 22nd 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, the University of Pennsylvania, discusses a study investigating differences in mutation rates between right- and left-sided colorectal cancer.

Cabozantinib Active in Neuroendocrine Tumors

January 22nd 2017

In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

January 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age

January 21st 2017

Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.

Progression Type in HCC Influences Survival Duration

January 21st 2017

Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.

Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

January 21st 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Dr. Finn on the Promise of Regorafenib for the Treatment of HCC

January 21st 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.

Trastuzumab Beyond Progression Shows Promise in HER2+ Gastric Cancers

January 21st 2017

Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

Surgical Palliation Enables Solid Food Intake in Advanced Incurable Gastric Cancer

January 21st 2017

Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.

Pembrolizumab/Ramucirumab Combo Active in Gastric Cancers

January 20th 2017

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

January 20th 2017

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

January 20th 2017

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs

January 20th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

PET-Guided Treatment Improves Outcomes in Esophageal Cancer

January 18th 2017

Switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy improved pathologic complete response rates in patients with esophageal and gastroesophageal junction cancers.